Tag: Vaccine
Dr Mansukh Mandaviya unveils ‘India’s Vaccine Growth Story’ at World Book...
India set an exemplary pro-vaccination Covid management model which resulted in saving 3.4 million lives
Should men also take HPV vaccinations to safeguard themselves?
The HPV vaccine must be actively given to the men as well women because it will prevent diseases like anal cancers specially in men who have men as sexual partners
UW-Madison Global Health Institute partners Ella Foundation to establish first-ever ‘UW-Madison...
Partnership expands the Wisconsin Idea by providing interdisciplinary collaborations with UW-Madison, the Ella Foundation, and Bharat Biotech
Vaccines with efficacy against Omicron variants will gain competitive advantage in...
According to GlobalData’s Pharma Intelligence Center, there are currently 19 COVID-19 vaccines in clinical development in China, with only 3 candidates in Phase III trials
Hester acquires tech from ICAR–NIHSAD to develop a low pathogenic Avian...
The agreement was signed on 27 December 2022 at the office of Agrinnovate India, New Delhi
Corbevax booster in individuals vaccinated with COVAXIN or COVISHEILD gives maximum...
As per AIG study, protein-based vaccine when given as a booster shown to induce not only increased antibody response but also robust T-cell and B-cell (memory cell) response linked with long-term immunity
Takeda’s tetravalent vaccine for Dengue approved for use in European Union
Effective dengue prevention requires a multi-faceted approach, and previous methods have been insufficient for a number of reasons
India will make significant investment in vaccine R&D, assures govt
While efforts are still on to uncover findings about the COVID-19 and the epidemiological models, India is ready to invest in future challenges
Intravacc launches phase I clinical trial of Avacc 10, an intranasal...
Randomized, double blinded, placebo-controlled trial. Evaluation of two doses in 36 volunteers. Mid-term data expected by end Q1 2023
Takeda’s dengue vaccine candidate granted priority review by US-FDA
TAK-003 is being evaluated for the prevention of dengue disease caused by any dengue virus serotype in individuals 4 years through 60 years of age